Compare Autodesk Inc (ADSK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Autodesk Inc trades at $250.6 (market cap $54.07B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Autodesk Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | VRTX | |
|---|---|---|
Market Cap | $54.07B | $132.79B |
Sector | Technology | Health |
52-Week High | $326.79 | $529.65 |
52-Week Low | $187.72 | $376.62 |
Enterprise Value | $53.87B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.08, up 2.73% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $6.13B in 2025, with net income reaching $1.11B and a 19.49% net margin. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $2.99 exceeding the $2.84 forecast. Analyst consensus is a Buy with a $305.31 price target, supported by 74.51% of analysts rating it a Buy. Recent news highlights AI investments and strategic acquisitions.
Outlook remains positive given robust earnings growth, high profitability margins, and strategic AI investments. Risks include competitive pressures in software, reliance on economic cycles affecting design software demand, and execution risks from recent acquisitions. The stock offers upside to the consensus target but faces volatility near technical resistance at $253.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
